echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Siddi declares CD47 monoclonal antibody

    Siddi declares CD47 monoclonal antibody

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 2nd, CDE accepted the clinical trial application for the CD47 monoclonal antibody drug 3D197


    3D197 is IMC-002, developed by ImmuneOncia


    In March 2021, Silodi introduced IMC-002 from ImmuneOncia


    IMC-002 is a fully human IgG4 monoclonal antibody designed to block the CD47-SIRPα interaction to promote the phagocytosis of cancer cells by macrophages


    This application is the first phase I clinical trial of 3D197 in China.


    According to a press release from Siddi, this antibody is expected to be used in combination with its PD-L1 product, envolimab, which is subcutaneously injected.


    Attachment: Pipeline of Siddi official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.